{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:03:04Z","timestamp":1793138584685,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40119-026-00457-5","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:09:37Z","timestamp":1782925777000},"page":"301-317","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cardiac Safety Outcomes in Delandistrogene Moxeparvovec Clinical Trials for Duchenne Muscular Dystrophy with Up to 5\u00a0Years of Follow-up"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3065-3956","authenticated-orcid":false,"given":"Aravindhan","family":"Veerapandiyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7857-9073","authenticated-orcid":false,"given":"John","family":"Bourke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9194-5330","authenticated-orcid":false,"given":"Jonathan H.","family":"Soslow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0086-9529","authenticated-orcid":false,"given":"John W.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8779-3220","authenticated-orcid":false,"given":"Craig M.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5269-4467","authenticated-orcid":false,"given":"Jerry R.","family":"Mendell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1255-5877","authenticated-orcid":false,"given":"Craig M.","family":"Zaidman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7649-9026","authenticated-orcid":false,"given":"Stefanie","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8809-4305","authenticated-orcid":false,"given":"Jianfeng","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6552-9152","authenticated-orcid":false,"given":"Mark","family":"Vivien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander P.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6303-8289","authenticated-orcid":false,"given":"Christoph","family":"Wandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"issue":"18","key":"457_CR1","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1161\/CIRCULATIONAHA.114.015151","volume":"131","author":"EM McNally","year":"2015","unstructured":"McNally EM, Kaltman JR, Benson DW, et al. Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy. Circ. 2015;131(18):1590\u20138.","journal-title":"Circ"},{"issue":"3","key":"457_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251\u201367.","journal-title":"Lancet Neurol"},{"issue":"6","key":"457_CR3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.rehab.2013.06.002","volume":"56","author":"P Kieny","year":"2013","unstructured":"Kieny P, Chollet S, Delalande P, et al. Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011. Ann Phys Rehabil Med. 2013;56(6):443\u201354.","journal-title":"Ann Phys Rehabil Med"},{"issue":"8","key":"457_CR4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.122.010040","volume":"16","author":"JH Soslow","year":"2023","unstructured":"Soslow JH, Xu M, Slaughter JC, et al. Cardiovascular measures of all-cause mortality in Duchenne muscular dystrophy. Circ Heart Fail. 2023;16(8):e010040.","journal-title":"Circ Heart Fail"},{"issue":"4","key":"457_CR5","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1080\/14740338.2024.2447072","volume":"24","author":"A Tang","year":"2025","unstructured":"Tang A, Yokota T. Is Duchenne gene therapy a suitable treatment despite its immunogenic class effect? Expert Opin Drug Saf. 2025;24(4):395\u2013411.","journal-title":"Expert Opin Drug Saf"},{"key":"457_CR6","unstructured":"Sarepta Therapeutics, Inc. ELEVIDYS (delandistrogene moxeparvovec-rokl) prescribing information. 2025. https:\/\/www.elevidys.com\/pi. Accessed 17 Dec 2025."},{"issue":"1","key":"457_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41598-024-84077-w","volume":"15","author":"RA Potter","year":"2025","unstructured":"Potter RA, Moeller IH, Khan S, et al. Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapy. Sci Rep. 2025;15(1):4.","journal-title":"Sci Rep"},{"issue":"3","key":"457_CR8","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.ymthe.2025.01.041","volume":"33","author":"CJ Walkey","year":"2025","unstructured":"Walkey CJ, Snow KJ, Bulcha J, et al. A comprehensive atlas of AAV tropism in the mouse. Mol Ther. 2025;33(3):1282\u201399.","journal-title":"Mol Ther"},{"issue":"9","key":"457_CR9","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","volume":"77","author":"JR Mendell","year":"2020","unstructured":"Mendell JR, Sahenk Z, Lehman K, et al. Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial. JAMA Neurol. 2020;77(9):1122\u201331.","journal-title":"JAMA Neurol"},{"issue":"7-8","key":"457_CR10","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1089\/hum.2019.255","volume":"32","author":"RA Potter","year":"2021","unstructured":"Potter RA, Griffin DA, Heller KN, et al. Dose-escalation study of systemically delivered rAAVrh74.MHCK7.micro-dystrophin in the mdx mouse model of Duchenne muscular dystrophy. Hum Gene Ther. 2021;32(7\u20138):375\u201389.","journal-title":"Hum Gene Ther"},{"issue":"23\u201324","key":"457_CR11","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1089\/hum.2024.013","volume":"35","author":"S Baine","year":"2024","unstructured":"Baine S, Wier C, Lemmerman L, et al. Long-term survival and myocardial function following systemic delivery of delandistrogene moxeparvovec in DMD(MDX) rats. Hum Gene Ther. 2024;35(23\u201324):978\u201388.","journal-title":"Hum Gene Ther"},{"issue":"1","key":"457_CR12","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","volume":"31","author":"JR Mendell","year":"2025","unstructured":"Mendell JR, Muntoni F, McDonald CM, et al. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase\u00a03 randomized trial. Nat Med. 2025;31(1):332\u201341.","journal-title":"Nat Med"},{"issue":"1","key":"457_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/mus.27955","volume":"69","author":"JR Mendell","year":"2024","unstructured":"Mendell JR, Sahenk Z, Lehman KJ, et al. Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: a phase\u00a01\/2a nonrandomized trial. Muscle Nerve. 2024;69(1):93\u20138.","journal-title":"Muscle Nerve"},{"key":"457_CR14","doi-asserted-by":"publisher","first-page":"1167762","DOI":"10.3389\/fcell.2023.1167762","volume":"11","author":"JR Mendell","year":"2023","unstructured":"Mendell JR, Shieh PB, McDonald CM, et al. Expression of SRP-9001 dystrophin and stabilization of motor function up to 2\u00a0years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy. Front Cell Dev Biol. 2023;11:1167762.","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"457_CR15","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/ana.26755","volume":"94","author":"CM Zaidman","year":"2023","unstructured":"Zaidman CM, Proud CM, McDonald CM, et al. Delandistrogene moxeparvovec gene therapy in ambulatory patients (aged \u22654 to <8 Years) with Duchenne muscular dystrophy: 1-year interim results from study SRP-9001-103 (ENDEAVOR). Ann Neurol. 2023;94(5):955\u201368.","journal-title":"Ann Neurol"},{"issue":"4","key":"457_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","volume":"31","author":"MF Naso","year":"2017","unstructured":"Naso MF, Tomkowicz B, Perry WL 3rd, Strohl WR. Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs. 2017;31(4):317\u201334.","journal-title":"BioDrugs"},{"key":"457_CR17","doi-asserted-by":"publisher","first-page":"175628642211497","DOI":"10.1177\/17562864221149781","volume":"16","author":"NL Goedeker","year":"2023","unstructured":"Goedeker NL, Dharia SD, Griffin DA, et al. Evaluation of rAAVrh74 gene therapy vector seroprevalence by measurement of total binding antibodies in patients with Duchenne muscular dystrophy. Ther Adv Neurol Disord. 2023;16:17562864221149780.","journal-title":"Ther Adv Neurol Disord"},{"key":"457_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.975803","volume":"13","author":"HCJ Ertl","year":"2022","unstructured":"Ertl HCJ. Immunogenicity and toxicity of AAV gene therapy. Front Immunol. 2022;13:975803.","journal-title":"Front Immunol"},{"issue":"6","key":"457_CR19","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.jacbts.2024.12.015","volume":"10","author":"A Forand","year":"2025","unstructured":"Forand A, Moog S, Mougenot N, et al. Long-term dystrophin replacement therapy in Duchenne muscular dystrophy causes cardiac inflammation. JACC Basic Transl Sci. 2025;10(6):759\u201382.","journal-title":"JACC Basic Transl Sci"},{"issue":"3","key":"457_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101273","volume":"32","author":"A Chhabra","year":"2024","unstructured":"Chhabra A, Bashirians G, Petropoulos CJ, et al. Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapies. Mol Ther Methods Clin Dev. 2024;32(3):101273.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"2","key":"457_CR21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1177\/22143602241303357","volume":"12","author":"BD Kaufman","year":"2025","unstructured":"Kaufman BD, Veerapandiyan A, Soslow JH, et al. Taking ACTION to detect myocarditis related to recombinant gene transfer therapy for Duchenne muscular dystrophy; consensus recommendations for cardiac surveillance. J Neuromuscul Dis. 2025;12(2):173\u201382.","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"457_CR22","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s40120-025-00879-8","volume":"15","author":"JR Mendell","year":"2026","unstructured":"Mendell JR, Muntoni F, McDonald CM, et al. Two-year outcomes following delandistrogene moxeparvovec treatment in ambulatory patients with Duchenne muscular dystrophy: phase\u00a03 EMBARK trial. Neurol Ther. 2026;15(2):545\u201359.","journal-title":"Neurol Ther"},{"key":"457_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.pediatrneurol.2024.01.003","volume":"153","author":"JR Mendell","year":"2024","unstructured":"Mendell JR, Proud C, Zaidman CM, et al. Practical considerations for delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy. Pediatr Neurol. 2024;153:11\u20138.","journal-title":"Pediatr Neurol"},{"issue":"5\u20136","key":"457_CR24","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1177\/10430342261423168","volume":"37","author":"PB Shieh","year":"2026","unstructured":"Shieh PB, Proud C, Diamond T, et al. Learnings from patient mortality after delandistrogene moxeparvovec administration: a report of two cases and Expert Committee considerations for future mitigation and management. Hum Gene Ther. 2026;37(5\u20136):262\u201379.","journal-title":"Hum Gene Ther"},{"issue":"10","key":"457_CR25","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/j.vaccine.2021.11.074","volume":"40","author":"SK Sexson Tejtel","year":"2022","unstructured":"Sexson Tejtel SK, Munoz FM, Al-Ammouri I, et al. Myocarditis and pericarditis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2022;40(10):1499\u2013511.","journal-title":"Vaccine"},{"issue":"6","key":"457_CR26","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1038\/s41390-021-01682-5","volume":"92","author":"A Sheybani","year":"2022","unstructured":"Sheybani A, Crum K, Raucci FJ, Burnette WB, Markham LW, Soslow JH. Duchenne muscular dystrophy patients: troponin leak in asymptomatic and implications for drug toxicity studies. Pediatr Res. 2022;92(6):1613\u201320.","journal-title":"Pediatr Res"},{"key":"457_CR27","unstructured":"Proud C, McDonald CM, Mercuri EM, et al. Pooled safety analysis from phase\u00a01 to phase\u00a03 clinical trials of delandistrogene moxeparvovec in Duchenne muscular dystrophy. Poster presented at: Muscular Dystrophy Association (MDA) Clinical and Scientific Conference; March 8\u201311, 2026; Orlando, FL, USA. Poster 478 LB."},{"issue":"10","key":"457_CR28","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/jamacardio.2018.2695","volume":"3","author":"ARA Abutaleb","year":"2018","unstructured":"Abutaleb ARA, McNally EM, Khan SS, Anderson AS, Carr JC, Wilcox JE. Myocarditis in Duchenne muscular dystrophy after changing steroids. JAMA Cardiol. 2018;3(10):1006\u201310.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"457_CR29","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s12872-025-04829-y","volume":"25","author":"M Mahdavi","year":"2025","unstructured":"Mahdavi M, Meshgi S, Hejri GM, Pouraliakbar H, Houshmand G. Diffuse active myocarditis in a teenager with Duchenne muscular dystrophy\u2014a case report. BMC Cardiovasc Disord. 2025;25(1):379.","journal-title":"BMC Cardiovasc Disord"},{"key":"457_CR30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2377-10-33","volume":"10","author":"S Mavrogeni","year":"2010","unstructured":"Mavrogeni S, Papavasiliou A, Spargias K, et al. Myocardial inflammation in Duchenne muscular dystrophy as a precipitating factor for heart failure: a prospective study. BMC Neurol. 2010;10:33.","journal-title":"BMC Neurol"},{"key":"457_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2025.105276","volume":"46","author":"M Schiava","year":"2025","unstructured":"Schiava M, Bourke JP, D\u00edaz-Manera J, et al. Association between age at loss of ambulation and cardiac function in adults with Duchenne muscular dystrophy. Neuromuscul Disord. 2025;46:105276.","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"457_CR32","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/mus.24163","volume":"50","author":"C Spurney","year":"2014","unstructured":"Spurney C, Shimizu R, Morgenroth LP, et al. Cooperative International Neuromuscular Research Group Duchenne Natural History Study demonstrates insufficient diagnosis and treatment of cardiomyopathy in Duchenne muscular dystrophy. Muscle Nerve. 2014;50(2):250\u20136.","journal-title":"Muscle Nerve"},{"issue":"1","key":"457_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2021-001592","volume":"8","author":"CF Spurney","year":"2021","unstructured":"Spurney CF, Ascheim D, Charnas L, et al. Current state of cardiac troponin testing in Duchenne muscular dystrophy cardiomyopathy: review and recommendations from the Parent Project Muscular Dystrophy expert panel. Open Heart. 2021;8(1):e001592.","journal-title":"Open Heart"},{"issue":"23","key":"457_CR34","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.3390\/diagnostics14232673","volume":"14","author":"ZQ Liu","year":"2024","unstructured":"Liu ZQ, Maforo NG, Magrath P, et al. MRI-based circumferential strain in boys with early Duchenne muscular dystrophy cardiomyopathy. Diagnostics (Basel). 2024;14(23):2673.","journal-title":"Diagnostics (Basel)"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00457-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-026-00457-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00457-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:23:38Z","timestamp":1788405818000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-026-00457-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["457"],"URL":"https:\/\/doi.org\/10.1007\/s40119-026-00457-5","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"3 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Aravindhan Veerapandiyan has received compensation for ad hoc advisory boards or consulting for Avidity, Biogen, Catalyst, Entrada Therapeutics, Gruenenthal, Insmed, Italfarmaco, Keros, Lupin, Mesoblast, Novartis, Pfizer, PTC Therapeutics, Precisionbio, RegenxBio, Sarepta Therapeutics, Scholar Rock, and Solid Biosciences. John Bourke is a Data Monitoring Committee member for Sarepta gene-therapy trials and is a scientific advisor to EspeRare Foundation, Pfizer, Roche, and Sarepta. Craig M. McDonald reports grants from Capricor Therapeutics, Catabasis, Edgewise Therapeutics, Epirium Bio, Italfarmaco, Pfizer, PTC Therapeutics, Santhera Pharmaceuticals, Sarepta Therapeutics, and Solid Biosciences and has a consultancy\/advisory role with BioMarin, Capricor Therapeutics, Catalyst, Edgewise Therapeutics, Italfarmaco, PTC Therapeutics, F. Hoffmann-La Roche Ltd, Santhera Pharmaceuticals, Sarepta Therapeutics, and Solid Biosciences; he has received honoraria from Edgewise Therapeutics, PTC Therapeutics, and Sarepta Therapeutics. Jerry R. Mendell received study funding from Sarepta Therapeutics while at Nationwide Children\u2019s Hospital at the time of the trials and is currently an employee of Sarepta Therapeutics and may own stock and\/or stock options in the company; he is also a co-inventor of rAAVrh74.MHCK7.micro-dys technology. Jonathan Soslow serves on the Data Monitoring Committee for Sardocor, receives research support from Ametris, is a consultant with Boehringer Ingelheim, Capricor, Catalyst, Dyne, Medpace, Sarepta, Secretome, Solid, and Wave, has served on advisory boards for Sarepta and Solid Biosciences, has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from NS Pharma, and may have Secretome stocks or stock options. John Day received grants or contracts from Edgewise Therapeutics, Novartis, Roche\/Genentech Pharmaceuticals, RegenxBio, and Sarepta Therapeutics; he has received consulting fees from Avidity Biosciences, Kate Therapeutics, Novartis, Sarepta Therapeutics, Scholar Rock, and Solid Biosciences. Craig M. Zaidman has received research support from Biogen and Novartis, and consulting fees from Guidepoint, and has served on an advisory board for Sarepta Therapeutics. Stefanie Mason was a Sarepta employee during the data generation and drafting of this manuscript and may own stock and\/or stock options in the company. Jianfeng Meng, Mark Vivien, and James Richardson are Sarepta employees and may own stock and\/or stock options in the company. Alexander P. Murphy and Christoph Wandel are Roche employees and may own stock and\/or stock options in the company.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All trials were performed in accordance with the ethical and scientific principles governing clinical research as set out in the Declaration of Helsinki, the principles of the International Council for Harmonisation\u2019s Guideline for Good Clinical Practice, and applicable laws and regulations. All trial protocols were reviewed and approved by the appropriate institutional review boards or independent ethics committees before trial initiation; appropriate informed consent was obtained.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}